A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.

Bacteria also defend themselves against pathogen attacks using mechanisms like those of the immune system. But if there is a ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...

Cortec GmbH implanted its brain-computer interface (BCI) system, Brain Interchange, into a stroke patient in late July, ...